ASO Author Reflections: High Stromal TGFBI is a Useful Predictive Marker for Nivolumab in Non-small Cell Lung Cancer
None of the authors have conflicts of interest to disclose.
- 5.Nakazawa N, Yokobori T, Kaira K, et al. High stromal TGFBI in lung cancer and intratumoral CD8-positive T cells were associated with poor prognosis and therapeutic resistance to immune checkpoint inhibitors. Ann Surg Oncol 2019-06-1409. 2019. https://doi.org/10.1245/s10434-019-07878-8.
© Society of Surgical Oncology 2019